TMCnet News
Viamet to Present at ICAAC/ICC 2015Viamet Pharmaceuticals, Inc. today announced that the company's antifungal product pipeline will be the subject of five presentations at the 2015 American Society for Microbiology (ASM (News - Alert)) Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Society of Chemotherapy (ISC) International Congress of Chemotherapy and Infection (ICC). The Conference will take place September 17-21, 2015 in San Diego, CA (News - Alert). Presentation details are as follows:
Oral Presentation (Slide Session 197)
Oral Presentation (Slide Session 197)
Poster Session 096 (Poster F-763a)
Poster Session 096 (Poster F-740)
Poster Session 105 (Poster M-848) About Viamet (www.viamet.com) Viamet discovers and develops breakthrough therapies based on our leadership in metalloenzyme chemistry and biology. Our clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. We also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. Focusing on the needs of patients and clinicians, we design our drug candidates to achieve superior safety and efficacy profiles compared to currently marketed drugs. This press release includes forward-looking statements. Actual results may vary materially from these statements. There are many important risks affecting Viamet's business, including that clinical trials may not be commenced, or if commenced, may not be successful, regulatory approvals may not be obtained and approved products, if any, may not achieve commercial success. The Viamet group of companies includes Viamet Pharmaceuticals Holdings, LLC and its operating subsidiaries, Viamet Pharmaceuticals, Inc., VPS-2, Inc. and VPS-3, Inc. The Viamet group of companies is based in the Research Triangle Park region of North Carolina, USA. View source version on businesswire.com: http://www.businesswire.com/news/home/20150910005873/en/ |